Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
Presenting a special experience to fans around the world.TOKYO--(BUSINESS WIRE)--ZAIKO will begin ticket sales on Sunday, June 15, 2025, at…
LONDON, June 5, 2025 /PRNewswire/ -- The World's 50 Best Restaurants 2025, sponsored by S.Pellegrino & Acqua Panna, today unveils…
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…
SHANGHAI, June 3, 2025 /PRNewswire/ -- On June 1, 2025, the 2025 Minions Banana Day was officially launched in Shanghai and…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…
June 03, 2025 01:00 ET | Source: Addex Therapeutics Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and…
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…
June 02, 2025 01:00 ET | Source: Wisekey International Holding Ltd. WISeKey to Present at Maxim Tech Conference “Discover the…